All News

At the time of data cutoff, 16 patients in cohort 1 and 27 patients in cohort 3 had been treated with TAR-210, an intravesical delivery system for erdafitinib.

The FDA has accepted a resubmitted biologics license application for N-803 for use in combination with BCG for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.

ARX517, a PSMA­-targeting antibody-drug conjugate, demonstrated favorable efficacy and safety in a phase 1/2 trial in patients with metastatic castration-resistant prostate cancer.

Using a case-based, interactive approach, this course is designed to offer practical clinical and surgical pearls for the management of women with complex pelvic floor disorders and complications.

Data showed a 20% reduced risk of recurrence or death among patients who received everolimus compared with placebo.

“Relugolix is the first approved ADT in Canada that can be administered orally, and once daily, offering a safe and effective option for advanced prostate cancer patients in the country," said Fred Saad, MD.

“There’s a 72% less chance of recurrence with oral erdafitinib than with standard of care. The problem is tolerability,” says James W.F. Catto, PhD, FRCS.

Treatment with the intravesical chemotherapy delivery system TAR-200 led to complete responses in over three-fourths of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer.

“As private equity firms increasingly engage in urology, key stakeholders, including policymakers and urologists, need to ensure that the quality of care is not compromised with the structural changes implemented after acquisition," write the authors.

“No doubt about it, this is unequivocally a positive trial by the rPFS criteria. Quite positive,” says A. Oliver Sartor, MD.

A post hoc analysis from the phase 3 CLEAR trial showed that frontline lenvatinib plus pembrolizumab elicited improved tumor response vs sunitinib across subgroups of patients with clear cell renal cell carcinoma.

“This is the first time [in urothelial carcinoma] we've managed to beat chemotherapy in the first-line setting for overall survival,” said Thomas B. Powles, MBBS, MRCP, MD.

Frontline therapy with nivolumab plus gemcitabine-cisplatin, followed by nivolumab maintenance, led to improved overall and progress-free survival in patients with unresectable or metastatic urothelial carcinoma.

Adding niraparib to abiraterone acetate and prednisone (AAP) was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.

“Belzutifan demonstrated a significant improvement in PFS with a hazard ratio of .75, and a significant P value. Similar findings were noted at the second interim analysis with a hazard ratio of .74,” says Laurence Albiges, MD, PhD.

“Future studies should focus on patient selection and the identification of positive predictive markers of response, more so than treating all comers, which several studies have shown has not really worked here or they acknowledge it,” says Julie N. Graff, MD.

“Belzutifan plus cabozantinib continue to show durable anti-tumor activity in patients with clear cell RCC who are treatment naïve or previously treated,” said Toni K. Choueiri, MD.

In a recent interview, Rohan Garje, MD, chief of genitourinary oncology at the Miami Cancer Institute, discussed the evolving paradigm with PARP inhibitors in prostate cancer.

Data from the study showed a median PSA-PFS of 13 months with the combination therapy compared with 7.8 months with enzalutamide alone.

The phase 3 EMBARK trial showed that enzalutamide plus leuprolide reduced the risk of metastasis or death by nearly 60% vs leuprolide alone in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Data showed noninferiority of subcutaneous nivolumab to intravenous nivolumab in the time-average to nivolumab serum concentration over 28 days (Cavgd28) and the trough serum concentration at steady state (Cminss).

"Many of the new codes are CPT Category III codes, which will require additional research for both coverage and payment rates, especially with private payers," write Jonathan Rubenstein, MD, and Mark Painter.

Treatment with TLX591 resulted in a PSA reduction in nearly two-thirds of evaluable patients with PSMA-expressing metastatic castration-resistant prostate cancer.

"Our data show no evidence of benefit from selenium and evidence of harm from vitamin E—a compound readily available over the counter," the authors write.

US and Chinese companies are partnering to bring the PSMA-PET imaging agent flotufolastat F 18 to the armamentarium for patients with prostate cancer in China.

Patients fear their personal data could be compromised, with 63% concerned increasing use of artificial intelligence will put their health information at risk.

The model may help identify patients with urothelial carcinoma who could benefit from PPARG inhibition through FX-909, a first-in-class small molecule inhibitor of PPARG.

“Our results provide molecular insights for potential therapeutic strategies to treat prostate cancer and other AR-involved diseases by targeting AR multivalent interactions,” said Zhijie “Jason” Liu, PhD.

Overall, 43.3% of patients who had received a diagnosis of NMIBC had 1 or more additional lesions detected with APL-1706 plus BLC compared with WLC alone.

Support for the NICE recommendation included 5-year results from the WATER trial, which showed that Aquablation had strong efficacy and safety vs transurethral resection of the prostate in patients with BPH.